Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study
Zhong Wang, Yimin Zhang, Feng Yao, Jinxin Li, Chenyuan Li, Shichong Liao · 2026
Read Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study by Zhong Wang, Yimin Zhang, Feng Yao, Jinxin Li, Chenyuan Li, Shichong Liao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13322814.txt.
Description
Zhong Wang and colleagues compare two follow-up treatments for HER2-positive breast cancer in a 2026 real-world study from Renmin Hospital of Wuhan University. Their group covers 184 people who still had invasive disease after drug treatment given before surgery, in records from 2019 to 2022.
One group received T-DM1 and the other received trastuzumab plus pertuzumab, with disease-free survival as the main measure. Disease progressed in fewer T-DM1 patients, and some higher-risk groups seemed to gain more, though the overall gap was not firm in statistical terms. Low platelet counts at a severe grade were more common with T-DM1, and no deaths were linked to treatment in either group.
Catalog record
| CREATOR | Zhong Wang, Yimin Zhang, Feng Yao, Jinxin Li, Chenyuan Li, Shichong Liao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22246 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |